Insider trade

Officer sold ~$478K of UTHR shares in the open market

Traded Oct 1, 2026 · Filed Oct 2, 2026

~$478K
Approx. value · 838 sh @ $570.90: 46K
Holds after · shares reported: −5.2%
stock since the trade · S&P 500 +2.0%, $571.38 → $541.62 on Oct 6

Why it stands out

United Therapeutics's & GENERAL COUNSEL sold $478K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Oct 1, 2026
Reporting period: Not applicable
Filed with the SEC: Oct 2, 2026

Officer$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$478,411

Shares × reported transaction price

Timing vs results

57 days after results of Aug 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $571.38 on Oct 1, 2026, within 5% of its 52-week high, after an 8% rise over the previous 30 trading days

52-week range $415.34 (Oct 28, 2025) to $596.76 (May 6, 2026), 86% of the way up, from 249 adjusted closes. 30 trading days earlier: $529.14 on Aug 19, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001231589-26-000021
Filed / recorded: Oct 2, 2026, 1:30 AM UTC
Added to OQRO: Oct 6, 2026, 9:34 PM UTC
Parser: form4-xml-v2
Data quality: Verified: identifiers matched exactly
Issuer: UNITED THERAPEUTICS Corp
Issuer CIK: 1082554
Ticker: UTHR
Reporting person: Paul A Mahon
Relationship: Officer
Officer title: EVP & GENERAL COUNSEL
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Oct 1, 2026
Transaction code: S
Shares / units: 838
Price per share: $570.90
Acquired / disposed: Disposed (D)
Shares owned after: 46,155
Ownership form: Direct
Amendment: No

Footnotes from the filing

This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
This transaction was executed in multiple trades at prices ranging from $570.405 to $571.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Around the same time

Martine A RothblattChairperson & CEO

Filed yesterday

9,500Shares · @ $117.76

Traded Oct 5 · filed 1 day later

Derivative exercise or conversion — not an open-market buy.

More Official record

Martine A Rothblatt (Chairperson & CEO) sold ~$269K of United Therapeutics

Scheduled in advanceFiled yesterday

Martine A Rothblatt (Chairperson & CEO) sold ~$486K of United Therapeutics

Scheduled in advanceFiled yesterday